In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three ...

In the field of cancer immunotherapy, unconventional T cells (UCTs) and Chimeric Antigen Receptor (CAR) T cells have emerged as promising areas of research ...

Severe autoimmune-mediated neuropathies, such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and ...

Using this approach, Neal et al. were able to produce the first open-source genome-wide perturbation atlas of cell morphology in human cells. The atlas contains 3 genome-wide genotype-phenotype maps ...

Third-generation CAR T-cell therapy shows promising efficacy and safety in heavily pretreated CLL patients, with a 67% complete response rate. The new CAR T-cell generation aims to mitigate ...

Your T cells work hard to fight disease. Unfortunately, "friendly fire" from T cells can sometimes harm the body's healthy ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

CAR T-cell therapy changes your immune cells to help them fight your cancer. It's a treatment for diffuse large B-cell lymphoma (DLBCL) that didn't respond to other treatments or that came back ...